



Crs Report for Congress: Authorized Generic Pharmaceuticals: Effects on Innovation: August 8, 2006 -Rl33605

By John R Thomas

Bibliogov, United States, 2013. Paperback. Book Condition: New. 246 x 189 mm. Language: English . Brand New Book ***** Print on Demand *****. The practice of authorized generics has recently been the subject of considerable attention by the pharmaceutical industry, regulators, and members of Congress alike. An authorized generic i 1/2sometimes termed a branded, flanking, or pseudo generici 1/2is a pharmaceutical that is marketed by or on behalf of a brandname drug company, but is sold under a generic name. Although the availability of an additional competitor in the generic drug market would appear to be favorable to consumers, authorized generics have nonetheless proven controversial. Some observers believe that authorized generics potentially discourage independent generic firms both from challenging drug patents and from selling their own products. These perceived disincentives result from the provisions of the Drug Price Competition and Patent Term Restoration Act of 1984. Better known as the HatchWaxman Act, this legislation provides independent generic firms with a reward for challenging patents held by brand-name firms. That bounty consists of a 180-day generic drug exclusivity period awarded to the first patent challenger. During the 180-day period, the brandname company and the first generic applicant are the only firms that...



READ ONLINE

Reviews

The publication is easy in read through safer to comprehend. It is actually loaded with wisdom and knowledge Its been printed in an extremely simple way and is particularly simply right after i finished reading through this pdf where actually modified me, affect the way i believe.

-- Ms. Clementina Cole V

This is the very best publication i have got read until now. It is definitely simplified but shocks within the fifty percent of the pdf. You may like how the article writer create this pdf.

-- Rosario Durgan